Biofrontera AG is a significant stockholder of the Company and, as a result of its control of the manufacture, clinical development and regulatory approval of Ameluz® may exert greater influence on the Company relative to the percentage of its ownership of the Company’s outstanding common stock. See “—Risks Related to Our Securities and Ownership of Our Common Stock— As of December 31, 2021, Biofrontera AG beneficially owns 46.8% of our stock after the completion of the initial public offering and will be able to exert significant control over matters subject to stockholder approval, and its interests may conflict with ours or other stockholders’ in the future” for more information on the risks related to Biofrontera AG’s beneficial ownership of the Company’s common stock.
Company profile
Ticker
BFRI, BFRIW
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
473765675
BFRI stock data
Latest filings (excl ownership)
8-K
Biofrontera Inc. Announces Preliminary Revenues
9 Jan 23
8-K
Departure of Directors or Certain Officers
16 Dec 22
DEFA14A
Additional proxy soliciting materials
8 Dec 22
DEFA14A
Additional proxy soliciting materials
29 Nov 22
DEFA14A
Additional proxy soliciting materials
21 Nov 22
424B3
Prospectus supplement
15 Nov 22
424B3
Prospectus supplement
15 Nov 22
10-Q
2022 Q3
Quarterly report
14 Nov 22
8-K
Biofrontera Inc. Reports Third Quarter 2022 Financial Results and Provides a Business Update
14 Nov 22
DEFR14A
Revised proxy
10 Nov 22
Latest ownership filings
4
Eugene Frederick Leffler
12 Jan 23
4
Erica F. Gates
12 Jan 23
3
Eugene Frederick Leffler
4 Nov 22
SC 13G
Abshagen Consulting GmbH
4 Nov 22
SC 13D/A
DEUTSCHE BALATON AKTIENGESELLSCHAFT
19 Sep 22
4
Erica L. Monaco
19 Sep 22
4
Hermann Luebbert
19 Sep 22
SC 13D
DEUTSCHE BALATON AKTIENGESELLSCHAFT
25 Aug 22
4/A
Loretta M. Wedge
6 Jun 22
4/A
Kevin Daniel Weber
6 Jun 22
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | |
|---|---|---|
| Revenue | ||
| Cost of revenue | ||
| Operating income | ||
| Operating margin | ||
| Net income | ||
| Net profit margin | ||
| Cash on hand | ||
| Change in cash | ||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 27.77 mm | 27.77 mm | 27.77 mm | 27.77 mm | 27.77 mm | 27.77 mm |
| Cash burn (monthly) | 1.45 mm | (no burn) | 1.21 mm | 1.56 mm | 1.09 mm | 15.00 k |
| Cash used (since last report) | 6.12 mm | n/a | 5.12 mm | 6.60 mm | 4.59 mm | 63.33 k |
| Cash remaining | 21.65 mm | n/a | 22.64 mm | 21.16 mm | 23.18 mm | 27.70 mm |
| Runway (months of cash) | 14.9 | n/a | 18.7 | 13.5 | 21.3 | 1846.8 |
Institutional ownership, Q3 2022
8.6% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 18 |
| Opened positions | 5 |
| Closed positions | 6 |
| Increased positions | 4 |
| Reduced positions | 4 |
| 13F shares | Current |
|---|---|
| Total value | 2.41 mm |
| Total shares | 2.31 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Deutsche Balaton Aktiengesellschaft | 1.18 mm | $1.41 mm |
| Bard Associates | 454.28 k | $337.00 k |
| Vanguard | 212.59 k | $223.00 k |
| BLK Blackrock | 118.59 k | $125.00 k |
| Schonfeld Strategic Advisors | 91.30 k | $96.00 k |
| Empery Asset Management | 75.00 k | $45.00 k |
| Geode Capital Management | 74.01 k | $77.00 k |
| Susquehanna International | 22.85 k | $14.00 k |
| NTRS Northern Trust | 20.73 k | $22.00 k |
| BMO Bank of Montreal | 15.00 k | $19.00 k |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 10 Jan 23 | Eugene Frederick Leffler | Employee stock option Common Stock | Grant | Acquire A | No | No | 0.9651 | 100,000 | 96.51 k | 100,000 |
| 22 Aug 22 | Hermann Luebbert | Common Stock | Option exercise | Acquire M | No | No | 0 | 113,379 | 0.00 | 113,379 |
| 22 Aug 22 | Hermann Luebbert | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 113,379 | 0.00 | 190,840 |
| 1 Jul 22 | Erica L. Monaco | Common Stock | Option exercise | Acquire M | No | No | 0 | 56,689 | 0.00 | 56,689 |
| 1 Jul 22 | Erica L. Monaco | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 56,689 | 0.00 | 152,672 |
News
Benchmark Reiterates Buy on Biofrontera, Lowers Price Target to $7
31 Jan 23
12 Health Care Stocks Moving In Wednesday's After-Market Session
18 Jan 23
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Jan 23
Biofrontera Announces First Patient Dosed In Pivotal Phase 3 Clinical Study Evaluating Ameluz(R)-PDT For The Treatment Of Actinic Keratosis On The Extremities, Neck And Trunk
9 Jan 23
Biofrontera Inc. Sees Prelim. Q4 Revenue $102.M-$10.4M
9 Jan 23
Press releases
Biofrontera Inc. Announces First Patient Dosed in Pivotal Phase 3 Clinical Study Evaluating Ameluz(R)-PDT for the Treatment of Actinic Keratosis on the Extremities, Neck and Trunk
9 Jan 23
Biofrontera Inc. Announces Preliminary Revenues for the Fourth Quarter and Full Year 2022
9 Jan 23
Biofrontera Inc. Announces Voting Results from 2022 Annual Meeting of Stockholders
16 Dec 22
Biofrontera Inc. to Participate in Benchmark's 11th Annual Discovery One-on-One Investor Conference
30 Nov 22
BIOFRONTERA INC. TO PARTICIPATE IN RENMARK'S VIRTUAL NON-DEAL ROADSHOW SERIES ON WEDNESDAY, NOVEMBER 30, MONDAY, DECEMBER 5, FRIDAY, DECEMBER 9, AND MONDAY, DECEMBER 19 2022
28 Nov 22